| Literature DB >> 19047180 |
Dominika Wokolorczyk1, Bartlomiej Gliniewicz, Andrzej Sikorski, Elzbieta Zlowocka, Bartlomiej Masojc, Tadeusz Debniak, Joanna Matyjasik, Marek Mierzejewski, Krzysztof Medrek, Dorota Oszutowska, Janina Suchy, Jacek Gronwald, Urszula Teodorczyk, Tomasz Huzarski, Tomasz Byrski, Anna Jakubowska, Bohdan Górski, Thierry van de Wetering, Swietlana Walczak, Steven A Narod, Jan Lubinski, Cezary Cybulski.
Abstract
Several genome-wide searches for common cancers have lead to the identification of a small number of loci that harbor low-risk cancer susceptibility markers. One marker, rs6983267 on chromosome 8q24, has been linked to both colon and prostate cancer, and is therefore a good candidate for a multicancer susceptibility marker. To determine the range of cancer sites associated with rs6983267, we genotyped 7,665 cases of cancer, representing 11 common cancer sites, and 1,910 controls. A significant odds ratio (OR) was observed for prostate cancer for carriers of genotype GG [OR, 1.77; 95% confidence interval (CI), 1.47-2.13]. The homozygote OR was higher for tumors with Gleason score 8 to 10 (OR, 1.94; 95% CI, 1.18-3.20) than for tumors with Gleason score 7 and below (OR, 1.65; 95% CI, 1.31-2.08). Significantly elevated (homozygote) ORs were observed for 4 other cancer sites, including colon (OR, 1.36; 95% CI, 1.08-1.72), kidney (OR, 1.52; 95% CI, 1.12-2.05), thyroid (OR, 1.37; 95% CI, 1.02-1.82), and larynx (OR, 1.39; 95% CI, 1.02-1.90). Information was available on family histories of cancer for eight sites. For six of the eight sites (prostate, breast, bladder, larynx, lung, and kidney), the homozygote ORs were higher for cases with a positive family history (at least one first-degree with any cancer) than for cases with unaffected first-degree relatives. Our results suggest that the range of cancers associated with the rs6983267 marker might be larger than previously thought.Entities:
Mesh:
Substances:
Year: 2008 PMID: 19047180 DOI: 10.1158/0008-5472.CAN-08-1838
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701